E Gromnica-Ihle

TL;DR: The associations found are in agreement with biological mechanisms and clinical observations and may help the clinician to adapt therapy with glucocorticoids accordingly and improve the benefit-risk ratio.

TL;DR: These data are the first to demonstrate that both depletion of the autoreactive immunologic memory and a profound resetting of the adaptive immune system are required to reestablish self-tolerance in SLE.

TL;DR: Discontinuation of long-term therapy with infliximab eventually led to relapse of disease activity in all patients but one and patients who were in partial remission according to the ASAS criteria and those with normal C-reactive protein levels at the time point of withdrawal had longer times to relapse after discontinuation of the treatment.

TL;DR: Treatment continuation of biological agents in clinical practice is less likely than in randomised clinical trials but more likely in comparable controls treated with conventional DMARDs.

TL;DR: Improvement in signs and symptoms of AS seen during the first year of the study was sustained during the second year and patients with AS treated for 2 years with infliximab exhibited a good and durable clinical response.